Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Prostatic Neoplasms 1Hot Flashes 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × fezolinetant × 90 days × Clear all
NCT06617455 2026-05-06

VEnT

University of Michigan Rogel Cancer Center

Phase 2 Terminated
9 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06917313 2026-05-06

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Yale University

Phase 2 Recruiting
92 enrolled
Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Chinese University of Hong Kong

Phase 2 Not yet recruiting
54 enrolled
Genitourinary

Prostatic Neoplasms

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡